Literature DB >> 23393225

Metabolomic and transcriptomic profiling of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.

Setsuko Yabushita1, Katsumi Fukamachi, Hajime Tanaka, Takako Fukuda, Kayo Sumida, Yoshihito Deguchi, Kazuki Mikata, Kazuhiko Nishioka, Satoshi Kawamura, Satoshi Uwagawa, Masumi Suzui, David B Alexander, Hiroyuki Tsuda.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most debilitating malignancies in humans, and one of the reasons for this is the inability to diagnose this disease early in its development. To search for biomarkers that can be used for early diagnosis of PDAC, we established a rat model of human PDAC in which expression of a human K-ras(G12V) oncogene and induction of PDAC are regulated by the Cre/lox system. In the present study, transgenic rats bearing PDAC and control transgenic rats with normal pancreatic tissues were used for metabolomic analysis of serum and pancreatic tissue by non-targeted and targeted gas chromatography-mass spectrometry and transcriptomic analysis of pancreatic tissue by microarray. Comparison of the metabolic profiles of the serum and pancreatic tissue of PDAC-bearing and control rats identified palmitoleic acid as a metabolite, which was significantly decreased in the serum of PDAC-bearing animals. Transcriptomic analysis indicated that several transcripts involved in anaerobic glycolysis and nucleotide degradation were increased and transcripts involved in the trichloroacetic acid cycle were decreased. Other transcripts that were changed in PDAC-bearing rats were adenosine triphosphate citrate lyase (decreased: fatty acid biosynthesis), fatty acid synthase (increased: fatty acid biosynthesis) and arachidonate 5-lipoxygenase activating protein (increased: arachidonic acid metabolism). Overall, our results suggest that the decreased serum levels of palmitoleic acid in rats with PDAC was likely due to its decrease in pancreatic tissue and that palmitoleic acid should be investigated in human samples to assess its diagnostic significance as a serum biomarker for human PDAC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23393225     DOI: 10.1093/carcin/bgt053

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  17 in total

Review 1.  Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.

Authors:  Julian Swierczynski; Areta Hebanowska; Tomasz Sledzinski
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

2.  N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis.

Authors:  Hui-Chang Bi; Yu-Zhuo Pan; Jing-Xin Qiu; Kristopher W Krausz; Fei Li; Caroline H Johnson; Chang-Tao Jiang; Frank J Gonzalez; Ai-Ming Yu
Journal:  Carcinogenesis       Date:  2014-08-12       Impact factor: 4.944

3.  In vivo18F-fluorodeoxyglucose-positron emission tomography/computed tomography imaging of pancreatic tumors in a transgenic rat model carrying the human KRASG12V oncogene.

Authors:  Koji Shibata; Katsumi Fukamachi; Atsushi Tsuji; Tsuneo Saga; Mitsuru Futakuchi; Masato Nagino; Hiroyuki Tsuda; Masumi Suzui
Journal:  Oncol Lett       Date:  2015-03-18       Impact factor: 2.967

Review 4.  Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.

Authors:  Henriette Berg Andersen; Renata Ialchina; Stine Falsig Pedersen; Dominika Czaplinska
Journal:  Cancer Metastasis Rev       Date:  2021-12-02       Impact factor: 9.264

5.  Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.

Authors:  Paige Yellen; David A Foster
Journal:  Cancer Lett       Date:  2014-07-30       Impact factor: 8.679

Review 6.  The complex landscape of pancreatic cancer metabolism.

Authors:  Cristovão Marques Sousa; Alec C Kimmelman
Journal:  Carcinogenesis       Date:  2014-04-17       Impact factor: 4.944

Review 7.  Glucose metabolic phenotype of pancreatic cancer.

Authors:  Anthony K C Chan; Jason I E Bruce; Ajith K Siriwardena
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

8.  HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer.

Authors:  Alan S Wang; Alessia Lodi; Lee B Rivera; Jose L Izquierdo-Garcia; Matthew A Firpo; Sean J Mulvihill; Margaret A Tempero; Gabriele Bergers; Sabrina M Ronen
Journal:  NMR Biomed       Date:  2014-09-09       Impact factor: 4.044

9.  The Intricate Metabolism of Pancreatic Cancers.

Authors:  Felipe Camelo; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Lipid droplet storage promotes murine pancreatic tumor growth.

Authors:  Jeremy J Grachan; Martin Kery; Amato J Giaccia; Nicholas C Denko; Ioanna Papandreou
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 4.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.